These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Reversal of a dabigatran overdose: what are possible options? Ratanapo S; Ungprasert P; Srivali N; Cheungpasitporn W; Bischof EF Am J Med Sci; 2013 Sep; 346(3):259. PubMed ID: 23974270 [No Abstract] [Full Text] [Related]
5. Dabigatran and bleeding: still an emergent situation? Van Heukelom J; Lal Y Am J Med Sci; 2013 Sep; 346(3):259. PubMed ID: 23698156 [No Abstract] [Full Text] [Related]
6. Dabigatran and postmarketing reports of bleeding. Southworth MR; Reichman ME; Unger EF N Engl J Med; 2013 Apr; 368(14):1272-4. PubMed ID: 23484796 [No Abstract] [Full Text] [Related]
7. Is there really misuse and abuse of dabigatran? Eikelboom JW; Hankey GJ Med J Aust; 2013 Apr; 198(7):358-9. PubMed ID: 23581946 [No Abstract] [Full Text] [Related]
8. The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine. Davis PK; Musunuru H; Walsh M; Mitra R; Ploplis V; Castellino FJ Thromb Haemost; 2012 Sep; 108(3):586-8. PubMed ID: 22782135 [No Abstract] [Full Text] [Related]
9. New era of oral anticoagulation for Japanese non-valvular atrial fibrillation patients. Hirano T Circ J; 2014; 78(6):1317-9. PubMed ID: 24805358 [No Abstract] [Full Text] [Related]
10. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study. Sølbeck S; Nilsson CU; Engström M; Ostrowski SR; Johansson PI Scand J Clin Lab Invest; 2014 Oct; 74(7):591-8. PubMed ID: 24909158 [TBL] [Abstract][Full Text] [Related]
14. Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series. Ross B; Miller MA; Ditch K; Tran M J Med Toxicol; 2014 Jun; 10(2):223-8. PubMed ID: 24385325 [TBL] [Abstract][Full Text] [Related]
15. Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran. Getta B; Muller N; Motum P; Hsu D; Zebeljan D; Rosenfeld D Br J Haematol; 2015 May; 169(4):603-4. PubMed ID: 25425051 [No Abstract] [Full Text] [Related]
16. Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices. Baumann Kreuziger LM; Reding MT Thromb Res; 2013 Aug; 132(2):e161-3. PubMed ID: 23916381 [No Abstract] [Full Text] [Related]
18. [Dabigatran and emergency operation on a peritonitis patient]. Ilmakunnas M; Louhimo J; Lassila R Duodecim; 2012; 128(7):753-7. PubMed ID: 22612026 [TBL] [Abstract][Full Text] [Related]
19. Uncontrollable haemorrhage following dabigatran prophylaxis. Sandhu PS; Wilson C; Dalton E; Bogdanov A BMJ Case Rep; 2013 Jun; 2013():. PubMed ID: 23761516 [TBL] [Abstract][Full Text] [Related]
20. Dabigatran, bleeding, and the regulators. Moore TJ; Cohen MR; Mattison DR BMJ; 2014 Jul; 349():g4517. PubMed ID: 25056265 [No Abstract] [Full Text] [Related] [Next] [New Search]